Juan Carlos
Montero González
Investigador desde 2021
Publicaciones (70) Publicaciones de Juan Carlos Montero González
2024
-
Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer
International Journal of Molecular Sciences, Vol. 25, Núm. 4
2023
-
An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer
Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200
-
Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival
International Journal of Molecular Sciences, Vol. 24, Núm. 9
-
Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer
International Journal of Biological Sciences, Vol. 19, Núm. 6, pp. 1731-1747
2022
-
Dysregulated Expression of Three Genes in Colorectal Cancer Stratifies Patients into Three Risk Groups
Cancers, Vol. 14, Núm. 17
-
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
2021
-
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia
Biomedicine and Pharmacotherapy, Vol. 144
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
PDCD4 limits prooncogenic neuregulin-ErbB signaling
Cellular and Molecular Life Sciences, Vol. 78, Núm. 4, pp. 1799-1815
-
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer
Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108
2020
-
Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer
International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14
-
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer
Cancer Letters, Vol. 491, pp. 50-59
-
Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer
Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127
2019
-
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1
-
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
Breast Cancer Research and Treatment, Vol. 174, Núm. 3, pp. 693-701
-
Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models
ACS Omega, Vol. 4, Núm. 8, pp. 13005-13014
2018
-
Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia [Oncotarget, 8 (2017) (29679-29698)] Doi: 10.18632/oncotarget.11425
Oncotarget
-
The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation
Molecular Oncology, Vol. 12, Núm. 7, pp. 1061-1076
2017
-
CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia
Oncotarget, Vol. 8, Núm. 18, pp. 29679-29698